Medicrea reported 3Q19 revenue of €8.2million (USD $9.2 million), +12.3% vs. 3Q18.
Growth was driven by strength in key markets like the U.S. (+17.8%) and Belgium (+15%)
In 3Q19, 500 surgeries were performed with Medicrea patient-specific implants, representing a 57% increase overall vs. the prior year (+77% in the U.S.)
The company anticipates reaching the 5000th cumulative implant of their patient-specific rods by the end of 2019
ORTHOWORLD projects Medicrea full year 2019 revenue of $37.7 million, +4.3% vs. 2018
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
3Q19
3Q18
$ Chg
% Chg
Spine
$7.7
$6.8
$0.9
13%
Orthobiologics
$1.5
$1.4
$0.1
9%
Total
$9.2
$8.2
$1.0
12.3%
9Mo 19
9Mo 18
$ Chg
% Chg
Spine
$22.7
$22.6
$0.1
0.6%
Orthobiologics
$4.6
$4.6
($0.0)
(0.6%)
Total
$27.3
$27.2
$0.1
0.4%
Geographic Sales
3Q19
3Q18
$ Chg
% Chg
US
$5.2
$4.4
$0.8
17.8%
Ex-US
$4.0
$3.8
$0.2
5.9%
Total
$9.2
$8.2
$1.0
12.3%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Medicrea reported 3Q19 revenue of €8.2million (USD $9.2 million), +12.3% vs. 3Q18.
Growth was driven by strength in key markets like the U.S. (+17.8%) and Belgium (+15%) In 3Q19, 500 surgeries were performed with Medicrea patient-specific implants, representing a 57% increase overall vs. the prior year (+77% in the U.S.) The...
Medicrea reported 3Q19 revenue of €8.2million (USD $9.2 million), +12.3% vs. 3Q18.
Growth was driven by strength in key markets like the U.S. (+17.8%) and Belgium (+15%)
In 3Q19, 500 surgeries were performed with Medicrea patient-specific implants, representing a 57% increase overall vs. the prior year (+77% in the U.S.)
The company anticipates reaching the 5000th cumulative implant of their patient-specific rods by the end of 2019
ORTHOWORLD projects Medicrea full year 2019 revenue of $37.7 million, +4.3% vs. 2018
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
3Q19
3Q18
$ Chg
% Chg
Spine
$7.7
$6.8
$0.9
13%
Orthobiologics
$1.5
$1.4
$0.1
9%
Total
$9.2
$8.2
$1.0
12.3%
9Mo 19
9Mo 18
$ Chg
% Chg
Spine
$22.7
$22.6
$0.1
0.6%
Orthobiologics
$4.6
$4.6
($0.0)
(0.6%)
Total
$27.3
$27.2
$0.1
0.4%
Geographic Sales
3Q19
3Q18
$ Chg
% Chg
US
$5.2
$4.4
$0.8
17.8%
Ex-US
$4.0
$3.8
$0.2
5.9%
Total
$9.2
$8.2
$1.0
12.3%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
